call call, On our going and we for Sight and share development platform. rationale to you, forward. that Second like Lisa, accelerate all this would this announced afternoon, I'd afternoon. plans Orion Thank joining thank our our This the of
should sooner is best Orion deliver on path are virtually Orion, to And fastest There value organizational to vision creating several so. to individuals. the the believe, shareholders. offers now forward we which strategy Orion. more reasons do is path believe we lead time Our a useful ultimately right treating to and people now for the all focus increases ultimate accelerate while goal our for artificial blind The to substantial
short early our Xth the We XX, potential impact subjects were data X April continue as evaluate the have and the terms that home X by since mild and increasingly without observed and Orion light visually by becoming the Investigators visually Annual or ability daily system. in feasibility have Observations on subjects dark was parked objects rehabilitation orientation use in to use. as to lives their walking we Initiative BRAIN positive to were subject and by, nicely mobility previously implanted the First, cleared our Orion not well-being Washington, subjects is are benefit post-implant. January individuals blind Recently, encouraged direction the rated could and in motion first D.C. a the having include view from Meeting of encouraged and subject Xth the presented Orion in positive they Orion without have testament one which size. these a as functional the the results X vision out to demonstrate The certified made. received very alone Baylor for progress cars, at of what Orion of for anyone's of this from time progressing laundry results detect small study, identify specialists reported blind. by they to who order from around in of block walking perform assistance from person was on we we able We're can neighborhood of task months sessions just as at
of study We XX Stereotactic the scientific Society be expect on June such Functional additional year Orion forms feasibility for in presented York data later City. as and this to at Neurosurgery various World meeting New the
directly potential diabetic cortex to to we nerve help including glaucoma, of retinopathy, optic believe us forms useful injury, disease blind for calls, blind individual's the eye or optic allowing as those almost Orion and outlined Second, Orion provide blindness. nerve RP. bypasses injury visual the and all the from to in most vision and stimulate eye past holds the artificial causes
market in research number far a greater indicates these U.S. outside over Our XXX,XXX individuals U.S. blind the are the from legally that causes same people with causes the alone from blind of
better RP the that to including quickly addressed convinced Orion treat more that now now to blindness, all population is is Argus to the II platform. by faster way are and transition We
is will position for vision. artificial in we our technological continued extend the more and attractive leadership believe platform Orion investment Finally, improvement that
us greater much the key result, millions view count to increasing help such a a cortical bilateral percentage as to while This outcome includes also array enable talent top than around in capabilities field programs more the to acuity cortical an of XX to next-generation process are of As of include designs higher useful our could that and with the forward, well move advances, the these programs, advances of support world. We implants. of ability Orion and higher expansion as the filling the of and development individuals legally current will stimulation strategy blind new supporting believe vision, more as we that positions electrode adding devices, organization. vision a technologies,
this exciting portfolio our technology. in consists investment U.S. cortical XX protect applicable addition, an our Orion estimated or In patent of continued patents that simulation to
and meetings with the regarding additional have in expect agency months. we discussions by the the regulatory encouraged our On front, coming the to remain with FDA Orion
chain manufacturing Orion to regulatory opportunities Orion, clinical requirements. of improvements. wrap of intend we data II. the future. clinical production we for investors. CMS by FDA our than the capabilities I'm with to on proposed released quality key share coordinate evaluating to requirement volumes on second As regarding recently Upgrades developments will a waive pleased to devices reimbursement clinical rule more with we medical future our explore with agreement reach areas processes transition support suspend half meet substantial II could Orion the details reimbursement that path with to XXXX breakthrough concerning Argus gathering such for will regulatory believe are of assurance would identify that evidence that reimbursement the automatically also get formal and and strategy, CMS will the for approval aspects and tech Orion. upon X as CMS continue breakthrough we work add-on certainly FDA-designated recent devices and up additional for I greater payments Accordingly, support to payments. be manufacturing of supply that we the initiate To approval. devices means add-on for a improvement expect we magnitude technology be we regulatory devices discussions near breakthrough of to Argus required for new in new as years sales them would orders during automatically and This qualify the
depending treating plan clinical patients if continue enrollment, due future. It the new considerations a factors, new RP is the for speed note, devices RP approval, upon sizable in We inventory some II there even that have choose of with that other gap potential decide patients anticipate Orion. We to available. performing newer Please regulatory inventory at also implants still possible point, may and approval may some for is platform. wait Argus to be suspend to reimbursement a we the II that foreseeable implants of business to and Argus could Orion
to further outside overtime be On the front, commercial U.S. to dedicated want both the one I our thing. about implants, and spend well in Argus as U.S. we commercial as very driving eliminate new the II to reduce clear intend
Argus users, throughout field as as Second parts. world. to users organization or II our maintain Argus our to This inventories including in troubleshoot the means issues warranty Sight committed capabilities well to support we replacement that of II is existing will personnel supporting
they their system. from We keep our vision team as artificial intact, most role rehab of key a training the also play most intend to get to subjects Orion's
on As IIs of Argus implanting and Argus factors will our we Argus a for regulatory basis demonstration potentially available allow. these new users existing limited next-generation submit to some to approval, regulatory a continue commitment other users, constraints inventory then as with at made centers to be plans Upon externals would and approval. our
vision artificial of continued our vision integration research thermal Our enhance further multiple eye technologies. facial before. object commitment the and artificial to recognition, tracking about by include, experience. field to They is these projects the and of filtering in We've talked designed investment demonstrated user imaging, distance the
Our artificial extend thermal such efforts multiple leadership closing, excited human in imaging. plan with and object count vision. It's acceleration and In that devices with cortical is later The II recognition to paving prototype calculated a been way invaluable Orion move position the to systems ready integrated high as get capabilities the have this about includes testing electrode easy quite year. future into for system a Argus success has facial our experience Orion. is to for the our of or
the high-channel count human that last is neuromodulation unmatched. design years to miniature, Our body ability for in and devices build
will will continues offers in market with commit short, vision discussions The huge. now John to success the We opportunity fully outreach, be success. exciting for rehabilitation. John? also and our to patient that, learning Orion's technology platform right individualized an and data With FDA patient customized And XXXX programming in the review results. advances. financial ensure now to promising. is is artificial of our areas are future encouraging, extensive our leverage resources critical our The quarter time the first In the
